- ReiThera has signed a Master Service Agreement (MSA) with SillaJen to manufacture the SJ-600 anticancer virus platform.
- The SJ-600 series features next-generation advancements, including enhanced intravenous delivery and repeat-dose potential.
ReiThera has entered into a Master Service Agreement (MSA) with SillaJen to support the manufacturing of the SJ-600 series, an innovative anticancer virus platform. The agreement appoints ReiThera as the Contract Development and Manufacturing Organization (CDMO) for the platform, enabling its progression to clinical trial readiness.
The SJ-600 series, developed by the SillaJen Research Institute in collaboration with Seoul National University College of Medicine, represents a major advancement in anticancer virus technology. This platform introduces features that allow repeated administration without neutralization reactions and improved intravenous delivery through the expression of complement regulatory protein ‘CD55’ on the virus surface.
Under the MSA, ReiThera will apply its expertise in viral manufacturing, particularly with viruses from the Vaccinia lineage, which forms the basis of the SJ-600 series. The Italy-based CDMO has decades of experience in manufacturing antinfective and cancer vaccines, as well as gene therapies.
Jang Dong-taek, CEO of SillaJen, stated, “Through collaboration with ReiThera, which has international vaccine development experience and the latest facilities, we are now able to promote standardized mass production of the SJ-600 series. This indicates that we have entered a further stage for licensing out the SJ-600 series.”
ReiThera’s CEO, Stefano Colloca, added, “We are thrilled to collaborate with SillaJen on the development and manufacturing of their innovative SJ-600 series. At ReiThera, we pride ourselves on leveraging our extensive experience with virus platforms, state-of-the-art facilities, and advanced expertise to support groundbreaking therapeutic solutions.”